^
    CANCER:

    Leiomyosarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    Progesterone receptor agonist
    megestrol
    1
    Multi-tyrosine kinase inhibitor
    pazopanib
    regorafenib
    2
    Alkylating agent, DNA inhibitor
    trabectedin
    3
    Aromatase inhibitor
    Aromatase inhibitor
    anastrozole
    4
    BMI1 inhibitor
    BMIi-1
    5
    PARP inhibitor
    PARP inhibitor
    olaparib
    6
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    7
    PD-L1 inhibitor, PARP inhibitor
    avelumab + talazoparib
    8
    ALK inhibitor
    alectinib
    crizotinib
    9
    DNA synthesis inhibitor, PARP inhibitor
    olaparib + temozolomide
    10
    AKT inhibitor
    capivasertib
    11
    CD70-targeted antibody-drug conjugate
    JNJ-0631
    12
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    13
    Glutaminase inhibitor
    IPN60090
    14
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    15
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    doxorubicin hydrochloride + dacarbazine
    16
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    17
    PD1 inhibitor, GM-CSF agonist
    nivolumab + talimogene laherparepvec
    18
    ATR inhibitor
    BAY 1895344
    19
    β-catenin inhibitor, XPO1 inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate + selinexor
    20
    MCSP inhibitor
    CSPG4.TNK
    21
    DNA synthesis inhibitor
    dacarbazine
    22
    PLK4 inhibitor
    CFI-400945
    No biomarker
    PGR positive
    ER positive
    FN1-ALK fusion
    HR positive
    ER positive + PGR positive
    RAD51B deletion
    AKT1 E17K
    TP53 mutation
    CD70 expression
    AKT1 mutation + mTOR mutation
    TMB-H
    PALB2 deletion
    BRCA2 mutation
    BRCA1 mutation
    HRD
    MYH9-ALK + ALK-WDR43
    PTEN mutation + TSC1 mutation
    NF1 mutation
    YWHAE-JAZF1 fusion
    Chr del(2)(p12)
    PLK4 expression
    Chr amplification(20)(p12.2)
    Chr amplification(4)(q26)
    ATRX mutation
    CSPG4 overexpression
    HAT1 overexpression
    MAN1A1-ROS1 rearrangement
    Chr del(2)(q14.1)
    Chr del(11)(q25)
    Chr amplification(13)(q13.3)
    Chr amplification(8)(q22.2)
    Chr amplification(8)(q13.2)
    Chr del(3)(q14.2)
    Chr del(1)(q44)
    Chr amplification(4)(q22.1)